What does this research mean for the field?

The small molecule SMAC modulates long-chain fatty acid uptake by the CD36 receptor, which has implications for therapeutic development in cancer, diabetes, and metabolic disorders. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To identify the small molecules binding site of the CD36 receptor and explore ligand recognition mechanisms.

March 3, 2026

Unveiling the Small Molecules Binding Site of CD36 Cell Surface Receptor Through Docking and Molecular Dynamics Simulations

Key Points

To identify the small molecules binding site of the CD36 receptor and explore ligand recognition mechanisms.
Conducted docking simulations to predict binding sites on CD36
Performed molecular dynamics simulations to observe receptor-ligand interactions
Analyzed structural features and critical residues involved in ligand binding
Identified key residues responsible for ligand recognition in CD36
Showed the significance of SMAC in enhancing LCFA uptake
Proposed implications for developing therapies targeting CD36-related conditions, such as cancer and diabetes

Abstract

This study highlights critical residues and structural features involved in ligand recognition by CD36. The identification of the SMAC and its role in modulating LCFA uptake provides promising insights for the development of therapeutic agents targeting CD36-related pathologies, including cancer, diabetes, and metabolic disorders.

Unveiling the Small Molecules Binding Site of CD36 Cell Surface Receptor Through Docking and Molecular Dynamics Simulations

Key Points

Abstract

Cite This Study